MLN 2201

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMLN 2201
Drug Alias NameMLN 01Anti-b2 monoclonal antibodyAnti-CD18 monoclonal antibody LDP-01LDP 01MLN-2201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin antagonists
TargetsIntegrin
Therapy Area/IndicationsReperfusion Injury
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsReperfusion Injury

Other Information

ATC CodeN/A
Related LinksN/A